HCWB News and Press, HCW Biologics Inc. From 08/03/22

MIRAMAR, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grad...

MIRAMAR, Fla., May 23, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grad...

HCW Biologics press release (NASDAQ:HCWB): Q1 GAAP EPS of -$0.06 beats by $0.05. Revenue of $1.79M. For further details see: HCW Biologics GAAP EPS of -$0.06 beats by $0.05, revenue of $1.79M

MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link betwee...

Cytokine-Based Fusion Proteins to Activate and Expand Memory-Like NK Cells Without Using Feeder Cells Sufficient for Off-the-Shelf Multi-Dose Adoptive Cell Therapy Cytokine-Based Fusion Proteins to Expand Human Regulatory T Cells That Circumvents Need for Magneti...

Preclinical data for lead investigational drug, HCW9218, in treatment of therapy-induced senescence in cancer Debut of preclinical data related to age-associated diseases MIRAMAR, Fla., April 19, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”...

Shares of HCW Biologics Inc. (NASDAQ:HCWB) traded today at $8.70, eclipsing its 52-week high. Approximately 22.2 million shares have changed hands today, as compared to an average 30-day volume of 42,000 shares. HCW Biologics Inc. (NASDAQ:HCWB) is currently priced 7.3% above its average ...

The following slide deck was published by HCW Biologics Inc. in conjunction with this event. For further details see: HCW Biologics Inc (HCWB) Presents At 2022 Virtual Growth Conference - Slideshow

HCW Biologics press release (NASDAQ:HCWB): Q4 Net loss of $3.2M cash balance was $11.7 million as of December 31, 2021 For further details see: HCW Biologics reports Q4 results

$56 Million IPO Completed in July 2021 Expected to Fund Operating Expenses through 2023 FDA Clearance for Initial Clinical Trials in Two Difficult-to-Treat Cancer Indications Publication of Three Pivotal Scientific Papers in Peer-Reviewed Journals MIRAMAR, Fla., Ma...